- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 15.09. | FDA reduces monitoring time for Amgen's Imdelltra infusions | ||
| 14.09. | No more Nordisk: Novo's latest trim is in its name | ||
| 14.09. | Scholar Rock's muscle-targeting SMA therapy Isemblyd lands FDA approval | ||
| 11.09. | HIV charities lament NICE snub for Gilead's twice-yearly lenacapavir | ||
| 11.09. | Exegenesis Bio and Modalis sign research deal for Duchenne therapy | ||
| 11.09. | ABEC to expand global manufacturing network with new Wilson facility | ||
| 10.09. | Encoded secures $275m for Dravet syndrome gene therapy | ||
| 10.09. | Bayer's Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion | ||
| 10.09. | HHS appoints permanent FDA CBER, CDER heads | ||
| 10.09. | Solstice Oncology secures $225m to drive porustobart's development for cancer | ||
| 10.09. | TwoStep Therapeutics secures $62.5m funding to advance TS-104 | ||
| 09.09. | Why China's rise needs to be taken with a pinch of salt | ||
| 09.09. | Pharma's R&D, commercial approach shifts amid global policy evolution | ||
| 09.09. | Moonwalk banks $70m to progress siRNA therapy for obesity | ||
| 09.09. | "Unparalleled opportunity": Sandoz embarks on ambitious biosimilar growth strategy | ||
| 09.09. | Gilead launches research facility in US for new medicine development | ||
| 09.09. | FDA grants RMAT designation to RiboX's RXRG001 for xerostomia | ||
| 09.09. | Quoin in line for priority review voucher if rare paediatric drug approved | ||
| 08.09. | Why the CNS boom owes its success to breakthroughs in neurological pathologies | ||
| 08.09. | Quoin in line for second priority review voucher if rare paediatric drug approved | ||
| 08.09. | UK on track to reverse years of pharma decline, ABPI report finds | ||
| 08.09. | LSTM opens $23m robotic AI lab for infection research | ||
| 08.09. | Novartis India acquires Pfizer brands for $132m | ||
| 07.09. | Mosquitos capable of transmitting dengue found breeding in UK for first time | ||
| 07.09. | Aptar Pharma to support Aceso's inhaled cystic fibrosis candidate's advance |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.